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Retinoic acid (RA) signaling is mediated by the retinoic acid receptor (RAR), belonging to the
nuclear hormone receptor superfamily. In addition to its classical transcriptional actions, RAR
also mediates rapid transcription-independent (nongenomic) actions, consisting in the acti-
vation of signal transduction pathways, as the phosphatidyl-inositol-3-kinase or the ERK
MAPK-signaling pathways. RA-induced rapid transcription-independent actions play a role in
different physiological contexts. As an effort toward understanding the functions of those
rapid actions on signaling elicited by RA, we have identified nuclear proteins the phosphor-
ylation state of which is rapidly modified by RA treatment in neuroblastoma cells, using a
proteomic approach. Our results show that RA treatment led to changes in the phosphoryla-
tion patterns in two families of proteins: 1) those related to chromatin dynamics in relation to
transcriptional activation, and 2) those related to mRNA processing and, in particular, mRNA
splicing. We show that treatment of neuroblastoma cells with RA leads to alteration of the
regulation of pre-mRNA splicing and mRNA translation. Thus, our results underscore novel
functions for the rapid signaling elicited by RAR in the regulation of mRNA processing. We
conclude that RA activation of signaling pathways can indeed regulate mRNA processing as
part of a cellular response orchestrated by the nuclear receptor RAR. (Molecular Endocrinology 23:
1799–1814, 2009)
Retinoic acid (RA), the biologically active formof vitaminA, is an important molecular signal for the early embry-
onic development and the differentiation of many cell types
(1–3). RA induces the differentiation of neuroblastoma cells
when added in vitro (4, 5), and a therapeutic effect for RA
has been demonstrated in a multicenter clinical assay with
high-risk neuroblastoma patients (6).
The actions of RA are mediated by two types of recep-
tors, retinoic acid receptors (RARs) and retinoid X recep-
tors (RXRs), belonging to the nuclear hormone receptor
superfamily, which encompasses receptors for steroid and
thyroid hormones, vitamins A and D, and other signaling
molecules. Members of this superfamily act as ligand-
gated transcriptional regulators (7), although rapid, tran-
scription-independent (also called nongenomic) actions
on signal transduction pathways have also been reported
(8). In addition to its well-characterized action as tran-
scriptional regulator, RA administration to neuroblas-
toma cells activates a transcription-independent signaling
response, which includes the rapid activation of impor-
tant signaling pathways as the phosphatidyl-inositol-3-
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kinase (PI3K)/Akt and the ERKMAPK pathways (9, 10).
The activation of PI3K by RA is required for neural dif-
ferentiation of neuroblastoma cells, because blocking
PI3K pathway with a specific inhibitor abolishes RA-in-
duced differentiation of SH-SY5Y cells (9). As a first ap-
proach to understand the physiological role of the tran-
scription-independent signaling response in the context of
the induction of neural differentiation by RA, we wanted
to identify the proteins that become rapidly phosphory-
lated as a consequence of RA treatment. We have re-
stricted our study to nuclear proteins, because our interest
is to confirm whether the rapid signaling response would
play a role on the gene expression changes occurring dur-
ing RA-induced differentiation. For this purpose, nuclear
phosphoproteins from control andRA-treated neuroblas-
toma cells were enriched by affinity chromatography. The
differences between the two phosphoprotein populations
were investigated using comparative [mass spectrometry
(MS) identification of differential spots in two-dimen-
sional electrophoresis (2DE)-gels] and quantitative [isolated
tags for relative and absolute quantification (iTRAQ) assay]
proteomic approaches. The results obtained show that the
changes in phosphorylation induced byRAoccurredmainly
in two families of nuclear proteins: 1) those related to chro-
matin dynamics involved in transcriptional regulation and
2) those related to mRNA processing and, in particular,
mRNA splicing. The involvement of rapid signaling re-
sponse in chromatin remodeling and transcriptional regula-
tion of steroid receptor target geneswas reported previously
(11–13), and participation of rapid transcription-indepen-
dent actions in nuclear receptor phosphorylation and co-
factor recruitment has been recently reported also for
the RAR (14). However, our results underscore novel
functions for the rapid transcription-independent sig-
naling elicited by RAR in the regulation of mRNA pro-
cessing. Indeed, we show experimental evidence sup-
porting that RA treatment of neuroblastoma cells
results in alteration of the regulation of mRNA splicing
and mRNA translation. In conclusion, we put forward
the idea that RA, through the rapid activation of sig-
naling pathways, could regulate mRNA processing, as
part of a cellular response orchestrated by the nuclear
receptor RAR.
Results
RA treatment of neuroblastoma cells results in
activation of downstream components of the
PI3K-signaling pathway
Treatment of SH-SY5Y neuroblastoma cells with RA
in vitro results in the rapid activation of the PI3K/Akt
signal transduction pathway (9, 10). Activation of PI3K/
Akt pathway downstream targets is also rapidly induced
by RA treatment, as shown in Fig. 1A. A rapid and tran-
sient activation of mammalian target of rapamycin
(mTOR) and p70S6 kinases was detectable after 10–30
min of RA treatment. A second, long-term activation
wave could be detected after 24 h of treatment. Activation
levels obtained by RA treatment are comparable to those
obtained by serum stimulation [30 min, 10% fetal bovine
serum (FBS)] of neuroblastoma cells. Activation of
mTOR and p70S6 kinases by RA appeared to be depen-
dent on PI3K activation because it was abolished by si-
multaneous administration of RA and the PI3K inhibitor
LY294002.
Use of a specific antibody against phosphoserine/thre-
onine residues within Akt kinase phosphorylation con-
sensus site (RXRXXS/T) revealed that RA treatment
increased rapidly the phosphorylation of several Akt
substrate proteins, detectable in whole-cell extracts (Fig.
1B; proteins of approximatelymolecularmass 70, 48, and
24 kDa and minor bands at 25–30 kDa) as well as in
nuclear extract (Fig. 1C; proteins of approximately mo-
lecular mass 60, 32, 30, and 27 kDa). 2-DEWestern blots
demonstrate that RA treatment leads to an increase in the
number and intensity of the spots corresponding to phos-
phorylated Akt substrates in nuclear extracts from neu-
roblastoma cells. In addition, new spots with significant
displacement toward the positive electrode could be de-
tected for some proteins (Fig. 1D).
A proteomic approach to the identification of
RA-induced phosphorylation changes in
nuclear proteins
As an attempt to understand the functions of the rapid
transcription-independent actions mediated by the RAR
nuclear receptor in the context of the cellular response to
RA, we wanted to identify the protein targets of the acti-
vated signaling pathways. By comparing the nuclear
phosphoproteomes from control and RA-treated cells, we
aimed to identify changes in the phosphorylation state of
nuclear proteins elicited by RA, which could give us in-
sight into the cellular function of the activated signaling
pathways. We assume that the overall levels of the pro-
teins remain unchanged during the short-term RA treat-
ment, and therefore the changes in the levels of phospho-
proteins will reflect changes in the stoichiometry of
phosphorylation. The study was restricted to nuclear pro-
teins because our interest was to confirm whether the
rapid signaling response would play a role on the gene
expression changes occurring during RA-induced differ-
entiation. In addition, a reduction in the complexity of the
protein samples would make the comparison easier.
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The general strategy followed is depicted in Fig. 2A.
Phosphoproteins from crude nuclear lysates from con-
trol and RA-treated (30 min, 1 M) neuroblastoma cells
were obtained with phosphoprotein columns (QIAGEN,
Hilden, Germany; 2.5 mg nuclear protein as
starting material). As shown in Fig. 2B, spe-
cific staining of phosphoproteins by ProQDi-
amond stain (15) showed an enrichment of
phosphoproteins in the eluate fraction, as
compared with the total protein staining with
SyproRuby. Similarly, Western blot with
Phospho-Ser- and Phospho-Tyr-specific anti-
bodies demonstrated the enrichment in pro-
teins containing these phosphorylated amino
acids in the eluted fractions (Fig. 2, C and D;
lanes labeled “EL1”). In this experiment, the
flow-through fraction from a first phospho-
protein purification column was loaded to a
second column. As shown in the figure, most
of the phosphorylated proteins were present
in the eluate of the first column, and only a
minimal fraction of phosphorylated proteins
was captured in the second purification step,
corresponding to apparently redundant pro-
tein species (Fig. 2, C and D; lanes labeled
“EL2”). Therefore, a single-column enrich-
ment protocol was used for the subsequent
experiments.
Phosphoprotein-enriched fractions from
control cells and from cells treated with RA
for 30 min were analyzed by 2DE, run with
isoelectrofocusing (pH 3–10) as first dimen-
sion and SDS-PAGE (12.5%) as the second.
Five pairs of 2DE-gels (control and RA-
treated extracts from independent experi-
ments) were run, stainedwith Coomassie bril-
liant blue (CBB), and compared with the aid
of a software package. A representative gel
pair is shown in Fig. 3A. Those spots showing
consistently a robust change trend (RA-control
ratio1.5-fold for increased spots;0.7-fold
for decreased spots) in at least three of the five
experiments were selected. In addition, those
spots having a significant displacement to-
ward the positive electrode were included.
Nine spots were selected in total (seven of
increased intensity, one showing displace-
ment toward acidic pH, and only one the in-
tensity of which decreased as the effect of RA
treatment. The average values for fold change
in intensity for the different spots are shown
in Fig. 3C. After tryptic digestion, we have
followed two MS-based protocols to identify
the proteins present in each spot. First we have used nano-
electrospray ionization using a Q-Trap mass spectrome-
ter, in which selected double- or triple-charged ions were
FIG. 1. RA treatment of neuroblastoma cells results in activation of downstream
components of the PI3K-signaling pathway. A, RA-induced activation of mTOR and
p70S6 kinases. SH-SY5Y neuroblastoma cells were treated with RA (1 M) for the times
indicated, and total cell extracts were prepared. For comparison, we included an
experiment in which cells were serum starved for 18 h and stimulated with 10% FBS for
30 min (lane labeled “FBS”). In addition, the extract from cells treated simultaneously
with LY294002 (10 M) and RA for 10 min was also included. The phosphorylation state
of mTOR and p70S6 kinases was analyzed by Western blot with specific antibodies
against the phosphorylated forms of the kinases (P-mTOR and P-p70S6). The filter was
reprobed finally with antibodies against total Akt (AKT). Each lane contains 30 g of total
protein. B, RA-induced phosphorylation of Akt substrates. SH-SY5Y neuroblastoma cells
were treated with RA (1 M) for the times indicated, and total cell extracts were prepared.
Each lane contains 30 g protein from whole-cell extracts. The phosphorylation state
of Akt substrates was analyzed by Western blot with specific antibodies against
phosphorylated Akt recognition site. Arrows show several RA-induced bands. C,
RA-induced phosphorylation of Akt substrates in the nucleus. SH-SY5Y neuroblastoma
cells were treated with RA (1 M) for the times indicated in the figure, and nuclear
extracts were prepared. Each lane contains 30 g protein from nuclear extracts. The
phosphorylation state of Akt substrates was analyzed by Western blot with specific
antibodies against phosphorylated Akt recognition site. Arrows show several RA-induced
bands. D, RA-induced phosphorylation of nuclear Akt substrates in 2DE-Western blots.
Each gel contains 30 g nuclear protein from cells treated with RA (30 min, 1 M) or
vehicle (Control). The phosphorylation state of Akt substrates was analyzed by 2DE-
Western blot with specific antibodies against phosphorylated Akt recognition site. Arrows
show prominent spots the signal of which is increased by RA treatment. LY, LY294002.
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fragmented [collision-induced dissociation-tandem MS
(MS/MS)] and the sequences of the peptides deduced from
the fragmentation spectra were obtained. The results are
shown in Table 1. In addition, peptide fingerprints were
obtained by matrix-assisted laser desorption ionization
(MALDI)-TOF (time of flight)/TOF for some of the spots
with a 4700 Proteomic Analyzer, and the identity of the
protein was deducedwith theMASCOT package (Table 2).
All nine spots were identified.
A first rapid validation experiment was performed by
checking the levels of five of the identified proteins in the
starting phosphoprotein-enriched extracts, through
Western blot immunodetection. As shown in Fig. 4, A and
B, all five proteins appeared increased to different extents
in the nuclear phosphoprotein extract from RA-treated
proteins. A second validation experiment was made using
2DE-Western blot immunodetection in unfractionated
nuclear extracts. RA-induced phosphorylation was vali-
dated when the treatment induced a spot displacement
toward acidic pH in 2DE-gels, which was abrogated by
incubating the extract with an unspecific protein phos-
phatase such as -protein phosphatase. As shown in Fig.
4, C–F, four of the five proteins assayed [histone H1.5,
high mobility group (HMG)B1, heterogenous nuclear ri-
bonucleoprotein (hnRNP), C1/C2, and hnRNP K] ful-
filled these criteria. In the case of histone H1.5, displace-
ment was not completely reverted by the treatment with
-phosphatase, suggesting that other posttranslational
modifications could contribute to the strong pH displace-
ment. The fifth protein assayed, nucleophosmin, could
not be validated because the antibody used gave inconsis-
tent patterns in 2DE-Western blot (data not shown). As
part of the validation experiments, we wanted to test
whether the RA-induced phosphorylation is a truly tran-
scription-independent event. We have analyzed the effect
of inhibiting transcription by actinomycin D (AMD)
treatment on RA-induced protein phosphorylation on
2DE-Western blots. As shown in Fig. 5, AMD treatment
did not affect RA-induced nuclear protein phosphoryla-
tion, and RA-induced spot displacement toward acidic
pH was detected in all four proteins assayed, similarly to
what was shown in the absence of the inhibitor in Fig. 4.
FIG. 2. Proteomic approach to the identification of RA-induced phosphorylation changes in nuclear proteins. A, General strategy. Neuroblastoma
cells were treated with RA or vehicle for 30 min, and nuclear protein extracts were prepared. Phosphoprotein-enriched fractions were obtained by
affinity chromatography, dialyzed with Nanosep spin columns, and loaded onto 2DE-gels (Isoelectrofocusing/SDS-PAGE). After electrophoresis, the
gels were stained with CBB and compared with the help of a conventional bioinformatic package (Bio-Rad PD-Quest), and the differential spots
were detected. The individual spots were isolated and digested with trypsin, and the proteins were identified by MS (peptide sequencing by CID-
MS/MS and/or MALDI-TOF/TOF peptide fingerprinting). B, Enrichment in phosphoproteins shown by phosphoprotein-specific staining. The
different fractions from the purification columns were run on SDS-PAGE gels, and the phosphoproteins were stained with ProQ-Diamond dye
(left). After documentation, the gel was destained and total proteins were stained with SyproRuby (right). Total nuclear lysate (load, L), flow-
through (FT), and phosphoprotein eluate (E) from control and RA-treated cells are shown (4 g protein per lane). *, Molecular mass markers
included ovalbumin (45 kDa, two phosphorylated residues). C, Enrichment in phosphoproteins shown by immunodetection of phosphorylated
amino acid residues. The different fractions from the purification columns were run on SDS-PAGE gels, transferred to nitrocellulose, and incubated
sequentially with specific antibodies against phosphoserine and phosphotyrosine. Whole-cell extract (WCE), nuclear lysate (load, L), flow-through
(FT1), and phosphoprotein eluate [EL1, from Control (C) and RA-treated cells (RA)]. In this experiment the flow-through fractions from the affinity
purification were loaded to a second phosphoprotein purification column and the flow-through fraction (FT2) and eluates [EL2, from Control (C),
and RA-treated cells (RA) from this second column are shown]. Each lane contains 25 g protein. For simplification only the WCE, L, FT1, and FT2
fractions from control cells are shown. The arrows point to protein bands that are present in the eluates from the second phosphoprotein
purification column (lanes labeled “EL2”).
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The experiments show that the strategy of phospho-
proteome comparison employed was useful to identify
nuclear proteins the phosphorylation state of which was
modified by RA treatment. Among the identified proteins
we could find proteins related to chromatin, such as his-
tone H1.5 or HMGB1. In addition, RNA-binding pro-
teins, such as nucleophosmin, hnRNP C1/C2, hnRNP K,
and PABP2 were also identified. However, the number of
identified protein species is low, probably because the
protocol relies on 2DE-gels stained with CBB, resulting in
low-sensitivity protein detection. In addition, known
2DE drawbacks, such as the difficulty in resolving large
proteins and too acidic or too basic proteins (16), could
show more influence in our experiment, because of the
nature of nuclear proteins.
Identification of RA-induced changes in
phosphorylation of nuclear proteins by iTRAQ
assay
One possibility for extending and improving our study
would be to use a 2DE-independent method, having
higher throughput, which would allow for
comparison of nuclear phosphoproteomes
and render quantitative results, such as the
iTRAQ system (isolated tags for relative and
absolute quantification (17); for recent re-
views see Refs. 18–20). For this purpose we
have used a strategy in which the enriched
phosphoprotein fractions of neuroblastoma
cells treated with RA for 15 and 30min or left
untreated were digested with trypsin and la-
beled independently with three of the iTRAQ
reporter reagents. The three samples were
combined and submitted to multidimensional
nanoliquid chromatography (LC). The 12
peptide-containing fractions obtained from
the first-dimension LC were submitted to the
second-dimension LC, and the selected frac-
tions were analyzed by tandemMS. The spec-
tra obtained were used to identify and quan-
tify proteins, using the Protein Pilot version
2.0 software.
We performed three independent iTRAQ
assays, with phosphoproteins obtained from
independent experiments. Approximately 150
different protein species could be identified
from the MS spectra (with confidence
95%). For each experiment the identified
proteins reported as having a statistically sig-
nificant fold change value with respect to the
untreated control (with P value  0.05) were
considered, and only those showing the same
change trend in at least two of the three ex-
periments were selected, with a total number of 63 differ-
ent protein species. From these 63 different proteins, the
phosphorylation of 36 of themwas increased as the effect
of RA treatments and the other 26 were dephosphory-
lated by the treatment. A protein belongs to the two
groups because it was detected as decreased at 15 min
treatment and increased at 30 min treatment. A complete
relation of these proteins and their relative fold change
values is shown in Tables 3 and 4.
In addition, the analysis detected 32 phosphorylated
peptides, eight of them corresponding to new phos-
phorylation sites previously not reported in the data-
bases (Table 5). However, only two phosphopeptides
could be identified as induced by the RA treatment with
enough statistical significance from the analysis of indi-
vidual phosphopeptides, corresponding to phosphory-
lated Ser residues in hnRNP-A1 (Ser6) and nucleophosmin
(Ser125). (Table 6).
For comparison, the results obtained in the iTRAQ
assay for the six proteins identified in the 2DE-gels are
FIG. 3. Comparison of nuclear phosphoprotein patterns from control and RA-
treated cells by 2DE. A, RA-induced changes in the patterns of nuclear
phosphorylated proteins. Representative 2DE gel pair with nuclear phosphorylated
protein samples from untreated (control) or RA-treated cells (1 M, 30 min). Each gel
was loaded with 125 g nuclear phosphorylated protein. Isoelectrofocusing (pH
3–10) was run as first dimension and SDS-PAGE (12.5%) was run as second
dimension. The gels were stained with CBB. Arrows mark the selected spots that
appeared increased (1–7), decreased (8), or displaced toward lower pH (9) as a
consequence of the RA treatment. B, Zoom-in detail of the regions including the
selected differentially expressed spots. C, Quantitative analysis of the differentially
expressed spots. Optical density was measured in five matched gel pairs from control
and RA-treated nuclear proteins for the selected spots (1–8). After normalization for
the total protein density, the mean and SD values were calculated for each of the
spots and represented as relative value (ratio RA/control).
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shown in Fig. 6A. All of them show the same change trend
as in the 2DE-based experiment, although the quantita-
tive values differ. In addition, a validation experiment
made with the same criteria as shown for Figs. 4 and 5 is
shown for HP1, one of the prominent proteins the phos-
phorylation of which appeared increased by RA in the
iTRAQ assay (Fig. 6, B and C).
A close inspection of the protein list shows again a
majority of proteins related to chromatin dynamics and
especially to RNA processing in a wide sense [RNA-bind-
ing proteins, hnRNPs, splicing factors (SFs) RNA heli-
cases, etc.]. The presence of multiple RNA/DNA helicases
among the dephosphorylated proteins appeared at least
striking. To try to find the biological significance of our
crude data, we have used the application FatiGO, in-
cluded in the Babelomics suite (21) to group the proteins
by biological process and molecular function. Among the
proteins with increased phosphorylation by RA treat-
ment, 40% belong to RNA binding (GO4), 19% to DNA
binding (GO4), 11% to both DNA and RNA binding,
and 11% to chromatin binding (GO3); 19% were as-
signed to other categories. For those the phosphorylation
of which was reduced by RA treatment, 33% belong to
RNA binding (GO4), 26% to DNA binding (GO4), 15%
to RNA/DNA binding, and 26% assigned to other cate-
gories; 38% belong to the category ATPase activity
(GO8) (Fig. 6D). With respect to biological process, the
proteins the phosphorylation of which is increased as a
consequence of RA treatment, 68% belong to RNA me-
tabolism (GO5), 41% to RNA splicing (GO7), 27% to
regulation of transcription (GO7), and 13% to RNA
splicing, via transesterification reactions with bulged
adenosine as nucleophile (GO9). Of those proteins
with decreased phosphorylation as an effect of RA
treatment, 63% belong to RNA metabolism (GO5),
38% to regulation of transcription (GO7), 31% to
RNA splicing (GO7), and 15% to RNA splicing, via
transesterification reactions with bulged adenosine as
nucleophile (GO9).
An effect of rapid signaling actions on the transcrip-
tional activity of nuclear receptors has been reported for
steroid hormones, acting especially at the level of chro-
matin remodeling, suggesting a convergence between
transcriptional and transcription-independent actions of
the receptor (11–13). Recently, an effect of rapidly acti-
vated pathways in RAR phosphorylation and cofactor
recruitment, resulting in increased transcriptional activa-
tion, has also been reported (14). In addition, our results
underscore the involvement of nuclear proteins engaged
in mRNA processing in a wide sense (splicing, transport,
translational regulation, etc.) in the cellular response to
RA. Therefore we propose as hypothesis that RA, through
the rapid activation of signaling pathways, could regulate
mRNA processing, as part of a cellular response orches-
trated by the nuclear receptor RAR.
TABLE 1. Identification of the differentially expressed spots by CID-MS/MS
Spot no. Identified protein SwissProt ID Sequenced peptides (position) Match E-value BLAST
1 Nucleophosmin P06748 DELHIVEAEAMNYEGSPIK (55–73) 19/19 2e-11
(NPM) MSVQPTVSLGGFEITPPVVLR (81–101) 21/21 1e-13
2 Histone H1.5 P16401 ATGPPVSELITK (38–49) 12/12 2e-04
ALAAGGYDVEK (68–78) 11/11 2e-03
3, 4 HMG box 1 (HMGB1) P09429 RPPSAFFLFCSEYRPK (97–112) 16/16 7e-10
5, 6 hnRNP-C1/C2 P07910 GFAFVQYVNER (51–61) 11/11 1e-04
MIAGQVLDINLAAEPK (74–89) 16/16 8e-09
7 hnRNP-K P61978 ILSISADIETIGEILKK (87–103) 17/17 2e-09
IILDLISESPIK (208–219) 12/12 5e-05
NLPLPPPPPPR (306–316) 11/11 1e-04
8 Polyadenylate-binding
protein-2 (PABP2)
Q86U42 GFAYIEFSDKESVR (214–227)
TSLALDESLFR (228–238)
14/14
11/11
4e-07
1e-03
ID, Identification.
TABLE 2. Identification of the differentially expressed spots by MALDI-TOF/TOF-based peptide fingerprinting
Spot no. Identified protein SwissProt ID
No. of different
matched peptides Coverage (%) Score MASCOT
2 Histone H1.5 P16401 2 12 70
3 HMG box 1 (HMGB1) P09429 13 67 368
5, 6 hnRNP-C1/C2 P07910 12 31 423
8 Polyadenylate-binding
protein-2 (PABP2)
Q86U42 7 32 71
9 Histone H1.5 P16401 11 41 316
ID, Identification.
1804 Laserna et al. RA-Induced Regulation of mRNA Processing Mol Endocrinol, November 2009, 23(11):1799–1814
RA treatment influences the regulation of
alternative splicing and mRNA translation via
activation of signaling pathways
We first examined whether RA treatment of neuro-
blastoma cells had any effect on the regulation of mRNA
splice site selection in vivo using the adenoviral E1Amini-
gene splicing reporter (22). This reporter generates a
splicing substrate containing competing splice sites allow-
ing changes in splice site usage to be detected from the
relative amounts of the different mRNA isoforms (Fig.
7A). After transfection of this reporter in neuroblastoma
cells, the mRNA was analyzed by RT-PCR. The results
showed that RA treatment altered the relative amounts of
the different spliced mRNA forms (Fig. 7, B and C). A
remarkable increase in the percentage of the 10S isoform
occurs as consequence of RA treatment (from 16.94 
1.08% to 26.51  0.87%). Treatment of the cells simul-
taneously with RA and the specific PI3K inhibitor
LY294002 abolished this change (16.23  2.36% and
15.93  3.65%, for control and RA-treated cells in the
presence of the inhibitor, respectively). However, RA-
induced increase in the isoform 10S is not affected by
inhibition of the ERK MAPK pathway by the specific
MAP-ERK kinase (MEK) inhibitor U0126 (17.79 
1.51% and 27.01  2.29% for control and RA-treated
cells in the presence of the inhibitor) (Fig. 7, B and C). The
amount of 10S mRNA isoform produced in RA-treated
cells and RAU0126-treated cells show statistically sig-
nificant differences with the control, whereas all the other
treatment showed no differences (P  0.002 in ANOVA
FIG. 4. Validation of the obtained results. A, Representation of the identified proteins in the phosphoprotein eluates. Each lane contained 30 g
protein from the eluates from control and RA-treated (1 M, 30 min) nuclear phosphoprotein fractions. Western blot membrane was incubated
sequentially with specific antibodies against nucleophosmin (NPM), Histone H1.5, HMGB1, hnRNP-C1/C2, and hnRNP-K. B, Quantitative analysis of
the experiment in panel A. The relative value (mean  SD from three independent experiments) for the intensity of each band was shown. C,
Validation of Histone H1.5 by 2DE-Western blot and phosphatase treatment. Nuclear proteins (25 g) from control cells and cells treated with RA
for 10 and 30 min, were run in 2DE-gels and transferred to nitrocellulose. Similarly, nuclear protein samples from control and RA-treated (1 M, 30
min) cells, obtained in the absence of protein phosphatase inhibitors were submitted to digestion with 400 U -protein phosphatase (1 h, 30 C) or
left untreated and were electrophoresed and transferred as above. The filters were incubated with specific antibodies for Histone H1.5. pH
gradient in isoelectrofocusing was 3–10. D, Validation of HMGB1 by 2DE-Western blot and phosphatase treatment. Nuclear proteins (25 g) from
control cells and cells treated with RA for 10 and 30 min were run in 2DE-gels and transferred to nitrocellulose. Similarly, nuclear protein samples
from control and RA-treated (1 M, 30 min) cells, obtained in the absence of protein phosphatase inhibitors, were submitted to digestion with 400
U -protein phosphatase (1 h, 30 C) or left untreated and were electrophoresed and transferred as above. The filters were incubated with specific
antibodies for HMGB1. pH gradient in isoelectrofocusing was 4–7. E, Validation of hnRNP-C1/C2 by 2DE-Western blot and phosphatase
treatment. Nuclear proteins (25 g) from control cells and cells treated with RA for 10 and 30 min, were run in 2DE-gels and transferred to
nitrocellulose. Similarly, nuclear protein samples from control and RA-treated (1 M, 30 min) cells, obtained in the absence of protein phosphatase
inhibitors, were submitted to digestion with 400 U -protein phosphatase (1 h, 30 C) or left untreated and were electrophoresed and transferred
as above. The filters were incubated with specific antibodies for hnRNP-C1/C2. pH gradient in isoelectrofocusing was 4–7. F, Validation of hnRNP-
K by 2DE-Western blot and phosphatase treatment. Nuclear proteins (25 g) from control cells and cells treated with RA for 10 and 30 min were
run in 2DE-gels and transferred to nitrocellulose. Similarly, nuclear protein samples from control and RA-treated (1 M, 30 min) cells, obtained in
the absence of protein phosphatase inhibitors, were submitted to digestion with 400 U -protein phosphatase (1 h, 30 C) or left untreated and
were electrophoresed and transferred as above. The filters were incubated with specific antibodies for HMGB1. pH gradient in isoelectrofocusing
was 4–7. Phos, Phosphatase.
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plus Bonferroni post hoc test). Therefore, we can con-
clude that RA treatment to neuroblastoma cells altered
the regulation of splice site selection, through PI3K-de-
pendent but ERK MAPK-independent mechanisms.
Among the proteins the phosphorylation of which is af-
fected by RA treatment, we could find the serine/arginine-
rich (SR) protein family, which are important regulators
of mRNA splicing (23). Splice site efficiency and specific-
ity are determined by critical protein-protein interactions
among pre-mRNA-binding proteins (24). Binding of U1
small nuclear ribonucleoprotein (snRNP)-70K protein to
the 5-splice site appears to be facilitated by serine/argi-
nine-rich (SR) proteins bound to specific sequences of the
pre-mRNA (23). Moreover, the interaction between SF2/
ASF (alternate splicing factor) and U1-70K protein is en-
hanced by phosphorylation of the SR protein (25). To test
whether RA treatment could influence the interactions
between SF2/ASF and U1-70K protein, we performed an
immunoprecipitation experiment in SH-SY5Y neuroblas-
toma cells. As shown in Fig. 7D, RA treatment rapidly
increased binding of SF2/ASF to U1-70K protein.
In addition to the actions of SR proteins in splicing,
several postsplicing activities have been described for a
subset of shuttling SR proteins, including regulation of
mRNA export and translation (26, 27). To analyze a pos-
sible influence of the activated signaling pathways on SR
protein-dependent translation, we used a translation re-
porter based on the fibronectin gene. The reporter con-
tained a luciferase coding sequence (LCS) harboring the
exonic splicing enhancer (ESE) as present in the fibronec-
tin extradomain A (EDA’s ESE; pLCS-EDA) or a mutant
version of this ESE (pLCS-EDAmt) that does not bind the
SR protein SF2/ASF (Fig. 8A and Ref. 26). After transfec-
tion to neuroblastoma cells, the relative activity from
pLCS-EDA over that obtained from pLCS-EDAmt in a
parallel experiment was measured. The results obtained
showed that RA treatment produced a modest but repro-
ducible increase in the translation of the reporter (1.7-
fold). This stimulation could be abrogated both by an
inhibitor of the PI3K/Akt pathway as well as by an inhib-
itor of the ERK-MAPK pathway (Fig. 8B). The results
suggest that RA treatment may affect the regulation of
translation of specific mRNAs through specific phos-
phorylation of members of the SR protein family. It has
been recently reported that the SR protein SF2/ASF pro-
motes translation initiation by enhancing the phosphor-
ylation of eIF4E-BP1, a competitive inhibitor of cap-de-
pendent translation, and therefore suppressing its activity
(28).Western blot immunodetection with a phospho-spe-
cific 4E-BP1 antibody showed a RA-induced increase in
the phosphorylation of 4E-BP1, which could be abolished
by simultaneous treatment with the PI3K inhibitor
LY294002, but not by treatment with the inhibitor of the
ERKMAPK pathwayU0126 (Fig. 8C). The effect of these
inhibitors on the activation of the PI3K/Akt signaling
pathway by RA has been analyzed. As expected,
LY294002 abolished the activation of Akt, mTOR, and
p70S6 kinases, as demonstrated by Western blot with
antibodies against the phosphorylated forms of the ki-
nases. However, treatment with U0126 did not affect the
activation of the three components of the PI3K/Akt path-
way by RA (Fig. 8D). Therefore, despite the good corre-
lation between mTOR activity and the phosphorylation
of 4E-BP1, as reported (28), additional mechanisms de-
pending on the activity of the ERK MAPK pathway ap-
pear to contribute to the establishment of a RA-depen-
dent mRNA translation control.
Discussion
The members of the nuclear hormone receptor superfam-
ily are involved in the transduction of the signals elicited
by different hormones and signaling molecules that have
profound effects on the physiology of the cells and con-
tribute to crucial aspects of differentiation, development,
and homeostasis in higher organisms. Nuclear hormone
receptors are known to act through two different types of
molecular actions, classified as transcriptional (genomic)
and transcription independent (nongenomic). Genomic
actions involve ligand-activated receptors bound to spe-
cific DNA elements in the promoter of their target genes,
resulting in the recruitment of coactivators and other fac-
tors that promote chromatin remodeling and ultimately
lead to transcriptional activation. Transcription-indepen-
dent actions consist in the rapid and transient activation of
kinase cascades throughmechanisms involving protein-pro-
FIG. 5. RA-induced changes in nuclear protein phosphorylation are
transcription independent. SH-SY5Y neuroblastoma cells were
pretreated with 1 g/ml AMD for 30 min before treatment with 1 M
RA for 30 min in the presence of the inhibitor. As control, cells were
treated with AMD alone. Nuclear proteins (25 g) from AMD-treated
cells and cells treated with RA for 30 min in the presence of the
inhibitor were run in 2DE-gels and transferred to nitrocellulose. The
filters were incubated with specific antibodies for Histone H1.5 (panel
A), HMGB1 (panel B), hnRNP-C1/C2 (panel C) and hnRNP-K (panel D).
pH gradient in isoelectrofocusing was 3–10 for histone H1.5 and 4–7
for HMGB1, hnRNP-C1/C2, and hnRNP-K.
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tein interactions between a subpopulation of nuclear recep-
tors and components of the signal transduction pathway. In
the case of RA we have previously shown that a subpopu-
lation of the nuclear receptor RAR interacts with p85, the
regulatory subunit of PI3K, and that this complex is located
at the plasma membrane after ligand activation (10).
Although it appears logical that both sides of the re-
sponse must integrate to achieve a coherent physiological
cellular response to a certain signal, little information is
available on the convergence of transcriptional and tran-
scription-independent actions in gene regulation by nu-
clear hormone receptors. To address that point, we have
identified proteins that become rapidly phosphorylated as
a consequence of RA treatment in neuroblastoma cells.
Because we wanted to confirm whether the rapid signal-
ing response would play a role on the gene expression
changes occurring during RA-induced differentiation,
our study was restricted to nuclear proteins. By compar-
ing the nuclear phosphoproteomes from untreated neuro-
blastoma cells and cells submitted to a short RA treat-
ment, we could identify nuclear proteins that are target
for the RA transcription-independent actions. The re-
sults obtained show that RA-induced phosphorylation
changes occurred mainly in two families of nuclear pro-
teins: those related to chromatin dynamics involved in
transcriptional regulation and those related to mRNA
processing and in particular mRNA splicing.
The involvement of rapid signaling response in chro-
matin remodeling and transcriptional regulation of ste-
roid receptor target genes has been reported (11–13), and
TABLE 3. Proteins identified in the iTRAQ assay as increased phosphorylation as effect of RA treatment (15 and
30 min)
Ratio RA/Control
Name Entry name Accession 15 min 30 min
Chromobox protein homolog 1 (HP1 ) CBX1_HUMAN P83916 1.2995 1.5161
Chromobox protein homolog 3 (HP1 ) CBX3_HUMAN Q13185 1.0964 1.1999
Chromobox protein homolog 5 (HP1 ) CBX5_HUMAN P45973 1.3438
hnRNP A/B ROAA_HUMAN Q99729 1.1215 1.3776
hnRNP A1 ROA1_HUMAN P09651 1.2672
hnRNP A3 ROA3_HUMAN P51991 1.1674
hnRNP D0 HNRPD_HUMAN Q14103 1.0895 1.3848
hnRNP G HNRPG_HUMAN P38159 1.3330
hnRNP K HNRPK_HUMAN P61978 1.3181
hnRNP Q HNRPQ_HUMAN O60506 1.7531
hnRNP A2 /B1a ROA2_HUMAN P22626 0.8863 1.1729
HMG protein B1 (HMGB1) HMGB1_HUMAN P09429 1.6989 2.1734
HMG protein B2 (HMGB2) HMGB2_HUMAN P26583 1.5223 2.0522
HMG protein HMG-I/HMG-Y (HMGA1) HMGA1_HUMAN P17096 1.2226 1.2954
SF, arginine/serine-rich 1, SF2/ASF (SFRS1) SFRS1_HUMAN Q07955 1.2281
SF, arginine/serine-rich 2, SC35 (SFSR2) SFRS2_HUMAN Q01130 1.2591
SF, arginine/serine-rich 3, SRp20 (SFRS3) SFRS3_HUMAN P84103 1.3765
SF, arginine/serine-rich 7, 9G8 (SFRS7) SFRS7_HUMAN Q16629 1.2293
SF, arginine/serine-rich 9, SRp30C (SFRS9) SFRS9_HUMAN Q13242 1.1152 1.2155
Arsenite-resistance protein 2 (ARS2) ARS2_HUMAN Q9BXP5 1.1642
Barrier-to-autointegration factor (BAF) BAF_HUMAN O75531 1.4720
Complement component 1 Q C1QBP_HUMAN Q07021 1.2706 1.1944
Drebrin DREB_HUMAN Q16643 1.5005
Nuclear protein Hcc-1 HCC1_HUMAN P82979 1.3270
Nucleolin (C23) NUCL_HUMAN P19338 1.2772 1.3237
Nucleophosmin NPM_HUMAN P06748 1.1112 1.3664
HRP-3-Hepatoma-derived growth factor-related protein 3 HDGR3_HUMAN Q9Y3E1 1.1239 1.4624
PC4 and SFRS1-interacting protein PSIP1_HUMAN O75475 1.1608 1.4093
Protein DEK DEK_HUMAN P35659 1.1637 1.3236
Protein RED RED_HUMAN Q13123 1.2171 1.2655
Protein SET SET_HUMAN Q01105 1.3899 1.5030
RNA-binding protein 8A RBM8A_HUMAN Q9Y5S9 1.2135 1.3512
Scaffold attachment factor B1 (SAFB1) SAFB1_HUMAN Q15424 1.1379
Splicing factor U2AF2 U2AF2_HUMAN P26368 1.2017
Tropomyosin (1, 2, 3, or 4) TPM3_HUMAN P06753 1.1642
U1 snRNP 70 kDa RU17_HUMAN P08621 1.4720
U4/U6.U5 tri-snRNP-associated protein 1 (SART1) SNUT1_HUMAN O43290 1.2706 1.1944
The name, the SWISS-PROT entry name and accession and the average values obtained for ratio RA/Control after 15 and 30 min RA treatment are
shown. Only statistically significant values are shown.
a hnRNP A2 /B1 is shown because it appears as decreased after 15 min and increased after 30 min RA treatment.
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participation of transcription-independent actions in nu-
clear receptor phosphorylation and cofactor recruitment
has been recently shown also for the RAR (14). In good
agreement with this idea, chromatin-binding proteins in-
volved in remodeling and transcriptional regulation con-
stitute an important part of the nuclear proteins the phos-
phorylation of which is affected by RA. Special mention
deserves the HP1 proteins, chromatin transcriptional re-
pressors whose phosphorylation was increased by RA
treatments. Transcriptional activation of theMMTVpro-
moter by steroid receptors results in displacement of
HP1, through a mechanism involving phosphorylation
of serine 10 of histone H3, mediated by transcription-
independent activation of members of the ERK MAPK
pathway (11, 12). Phosphorylation of HP1 proteins im-
pairs its repression activity (29), and therefore our results
TABLE 5. Phosphorylation sites detected not present in the PhosphoSitePlus database (http://www.phosphosite.org) or
Uniprot Protein KB (www.uniprot.org)
Accession Protein
Phospho-
residue Peptide sequence
Q9UIG0 Bromodomain adjacent to zinc finger
domain protein 1B (BAZ1B)
Thr661 VLVILLQ(Pho)TLLQDEIAEDYGELGMK
Q14839 Chromodomain helicase-DNA-binding
protein 4 (CHD-4)
Thr242/Thr244 GSSGASVAAAAAAAVAVVESMV(Pho)TA(Pho)TEVAPPPPPVEVP
P61978 hnRNP K Ser127 IIPTLEEGLQLPSPTATSQLPLE(Pho)SDAVECLNYQHYK
Q6FI13 Histone H2A type 2-A (H2A2A) Thr60 VGAGAPVYMAAVLEYL(Pho)TAEILELAGNAAR
GAPVYMAAVLEYL(Pho)TAEILELAGNAAR
Q8IUE6 Histone H2A type 2-B (H2A2B) Thr60 VGAGAPVYLAAVLEYL(Pho)TAEILELAGNAAR
Q15424 Scaffold attachment factor B1 (SAFB1) Thr340 TDCEPVGLEPAVEQSSAASELAEASSEELAEAP(Pho)TEAPSPEAR
Q14151 Scaffold attachment factor B2 (SAFB2) Thr339 TDCEPVGLEPAVEQSSAASELAEASSEELAEAP(Pho)TEAPSPEAR
TABLE 4. Proteins identified in the iTRAQ assay as decreased phosphorylation as effect of RA treatment (15 and
30 min)
Name Entry name Accession
Ratio RA/control
15 min 30 min
ATP-dependent DNA helicase 2 subunit 1 (70 kDa subunit) (Ku70) KU70_HUMAN P12956 0.7945
ATP-dependent DNA helicase 2 subunit 2 (80 kDa subunit) (Ku80) KU86_HUMAN P13010 0.7280
ATP-dependent RNA helicase A (DHX9) DHX9_HUMAN Q08211 0.8278 0.7545
ATP-dependent RNA helicase DDX39 DDX39_HUMAN O00148 0.8219
Probable ATP-dependent RNA helicase DDX5 DDX5_HUMAN P17844 0.7272
Spliceosome RNA helicase BAT1 UAP56_HUMAN Q13838 0.8312
Nucleolar RNA helicase 2 DDX21_HUMAN Q9NR30 0.8583 0.7812
hnRNP U HNRPU_HUMAN Q00839 0.9095
hnRNP U-like protein 1 HNRL1_HUMAN Q9BUJ2 0.7133
hnRNP A2 /B1a ROA2_HUMAN P22626 0.8863 1.1729
60S ribosomal protein L22 RL22_HUMAN P35268 0.7105
Bromodomain adjacent to zinc finger domain protein 1B BAZ1B_HUMAN Q9UIG0 0.7057
General transcription factor II-I (GTFII-I, TFII-I) GTF2I_HUMAN P78347 0.8136
Histone H3 (1, 2, or 3) H32_HUMAN Q71DI3 0.7324
Histone H4 H4_HUMAN P62805 0.6955
Histone-binding protein RBBP4 RBBP4_HUMAN Q09028 0.8323
Lamin-B1 LMNB1_HUMAN P20700 0.8128
Non-POU domain-containing octamer-binding protein NONO_HUMAN Q15233 0.7489
Nucleolar protein 5 (NOP5) NOL5_HUMAN Q9Y2  3 0.7909
Nuclear mitotic apparatus protein 1 (NUMA1) NUMA1_HUMAN Q14980 0.7394
SF, proline- and glutamine-rich (SFPQ) SFPQ_HUMAN P23246 0.8739
Protein RRP5 homolog RRP5_HUMAN Q14690 0.6680
RNA-binding protein Raly RALY_HUMAN Q9UKM9 0.8642
SWI/SNF-related matrix-associated actin-dependent regulator of
chromatin subfamily A member 5 (SMARCA5)
SMCA5_HUMAN O60264 0.6833
Tubulin 	chain (A, B, or C) TBA1A_HUMAN Q71U36 0.8116
U5 snRNP 200 kDa helicase (U5-200KD) U520_HUMAN O75643 0.8612
Ubiquitin UBIQ_HUMAN P62988 0.8675 0.8993
The name, the SWISS-PROT entry name and accession, and the average values obtained for ratio RA/Control after 15 and 30 min RA treatment are
shown. Only statistically significant values are shown.
a hnRNP A2 /B1 is shown because it appears as decreased after 15 min and increased after 30 min RA treatment.
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suggest that phosphorylation of HP1 proteins through
rapid signaling actions of RAR could also contribute to
the establishment of active chromatin and ultimately to
gene activation.
The presence of a considerable number of RNA-bind-
ing proteins involved in mRNA processing and, in partic-
ular, mRNA splicing among those whose phosphoryla-
tion was modified by RA treatment uncovered the
FIG. 6. Quantitative phosphoprotein comparison by iTRAQ analysis. A, Quantitative analysis by iTRAQ of the proteins identified by 2DE. The
values obtained for change ratio (RA, 30 min/control) in mean  SD from three independent iTRAQ assays was represented for the proteins
identified with the 2DE-gel-based approach. In comparison, the change trend is the same for all proteins, but the fold change values obtained are
lower for H1.5, hnRNP-C1/C2, and PABP2. For PABP2 the value taken was the one at 15 min RA treatment, because at 30 min RA treatment the
value obtained was statistically not significant. B, Representation of HP1 protein in the phosphoprotein eluates. Each lane contained 30 g
protein from the eluates from control and RA-treated (1 M, 30 min) nuclear phosphoprotein fractions. Western blot membrane was incubated
with specific antibodies against HP1. A quantitative analysis of the experiment is shown. The relative value (mean  SD from three independent
experiments) for the ratio of intensity of the band in the RA-treated eluate against that appearing in the control eluate is shown. C, Validation of
HP1 by 2DE-Western blot, phosphatase treatment, and AMD treatment. Nuclear proteins (25 g) from control cells and cells treated with RA for
10 and 30 min were run in 2DE-gels and transferred to nitrocellulose. Similarly, nuclear protein samples from control and RA-treated (1 M, 30 min) cells,
obtained in the absence of protein phosphatase inhibitors, were submitted to digestion with 400 U -protein phosphatase (1 h, 30 C) or left untreated
and were electrophoresed and transferred as above. RA-induced phosphorylation of HP1 is transcription independent. Finally, nuclear proteins (25 g)
from AMD-treated cells and cells treated with RA for 30 min in the presence of the inhibitor were run in 2DE-gels and transferred to nitrocellulose. The
filters were incubated with specific antibodies for HP1. pH gradient in isoelectrofocusing was 4–7. D, Functional annotation of the differentially
expressed phosphoproteins (increased in RA-treated, left; decreased in RA-treated, right) according to molecular function. Phos, Phosphatase.
TABLE 6. Peptides detected as increased in phosphorylation as consequence of RA treatment with
confidence 95%
Protein Accession Peptide sequence Residue N
RA-15 min RA-30 min
Mean SD Mean SD
hnRNP-A1 P09651 SE(Pho)SPKEPEQLR Ser6 12 1.37 0.15 1.53 0.23
NPM P06748 CGSGPVHISGQHLVAVEEDAE(Pho)SEDEEEEDVK Ser125 10 1.21 0.24 1.39 0.28
N represents the number of times that the peptide was identified in independent MS spectra.
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involvement of nuclear proteins engaged in mRNA pro-
cessing in a wide sense (splicing, transport, translational
regulation, etc.) in the cellular response to RA. Therefore
we proposed as hypothesis that RA, through the rapid
transcription-independent activation of signaling path-
ways, could regulate mRNA processing as part of a cel-
lular response elicited by the nuclear receptor RAR. Con-
sequently, we have found that RA treatments, through the
activation of signaling pathways, regulate splice site se-
lection in a simple assay as the E1A minigene splicing
reporter. Splice site efficiency and specificity are deter-
mined by critical protein-protein interactions among pre-
mRNA-binding proteins (24). Among the proteins the
phosphorylation of which is affected by
RA treatment, we could find members
of the serine/arginine-rich (SR) protein
family, which are important regulators
of mRNA splicing (23). Binding of U1
snRNP-70K protein to the 5-splice site
appears to be facilitated by SR proteins
bound to specific sequences of the pre-
mRNA (23). We show that RA treat-
ment promotes interactions among SFs
such as SF2/ASF and U1-snRNP-70K
protein, interactions that appear to rely
on the phosphorylation of SF2/ASF
(25). Much evidence supports the idea
that signaling pathways could regulate
alternative splicing, by phosphorylating
RNA-binding proteins that are constit-
uents of the spliceosome and/or func-
tion as splicing regulatory factors (30–
32). Thismechanism appears to overlap
with the cotranscriptional coupling of
RNA synthesis and splicing, previously
reported for steroid receptors (33–36).
Nevertheless, cotranscriptional splicing
regulation relies on transcriptional co-
activators bound to nuclear hormone
receptors, therefore acting only on re-
ceptor target genes (33–36).
Translational control is an impor-
tant strategy by which eukaryotic cells
regulate gene expression. Translation is
the last step in the genetic information
flow, and regulation at this level allows
a rapid response to different regulatory
signals. We have also explored the pos-
sibility that RA-induced rapid signaling
also affects specific mRNA transla-
tional efficiency. Several postsplicing
activities have been described for a sub-
set of shuttling SR proteins, including
regulation of mRNA export and translation (26, 27). By
using a translation reporter based on the fibronectin gene
including binding sites for the SR factor SF2/ASF (26), we
could show that RA treatment produced an increase in the
translation of this reporter. This stimulation appeared to
be dependant both on the activity of PI3K/Akt as well as
the ERK-MAPK pathways. The results suggest that
through specific phosphorylation of members of the SR
protein family, RA treatment may affect the regulation of
the translation of specific mRNAs. It has been recently
reported that the SR protein SF2/ASF promotes transla-
tion initiation by enhancing the phosphorylation of
FIG. 7. RA treatment influences the regulation of alternative mRNA splicing via activation of
signaling pathways. A, Schematic representation of the alternative splicing forms in the E1A
minigene reporter and the RT-PCR fragments obtained from the different mRNA isoforms
generated. [Adapted from Ref. 40]. B, Effect of RA treatment on the regulation of splice site
selection. After transfection of the E1A minigene reporter, neuroblastoma cells were treated
with 1 M RA (24 h), plus LY294002 (10 M) or U0126 (10 M) as indicated. Total RNA was
obtained, and the different splicing variants were detected by RT-PCR. After electrophoresis
in an agarose gel, the bands were stained with ethidium bromide. C, Control cells; RA, RA-
treated cells; LY, cells treated with the PI3K inhibitor LY294002 (10 M); U0126, cells treated
with the MEK inhibitor U0126 (10 M). C, Quantitative analysis of the experiment shown in
Fig. 6B. The relative percentages of the different mRNA isoforms generated by alternative
splicing and the effect of the different treatments are shown. The graph includes the data
from three independent experiments. Stippled bars, 13S; shadowed bars; 12 S; solid bars,
10S; open bars, 9S. Asterisks on the 10S isoform in RA and RAU0126 samples indicate
statistically significant differences with respect to control (P  0.002). All the other samples
were not statistically different from control (ANOVA plus Bonferroni post hoc test). D, RA
treatment enhanced the interaction between SF2/ASF and the U1 snRNP-70K protein.
Nuclear extracts were prepared from neuroblastoma cells treated with 1 M RA for 0, 15,
and 30 min. About 200 g of nuclear proteins was incubated with 4 g of SF2/ASF
monoclonal antibody (lanes labeled “SF2”). As control, a parallel reaction was set with 4 g
of an unrelated antibody (lane labeled “IgG”). Nuclear extracts (25 g) from cells treated
with 1 M RA for the times indicated in the figure were included for comparison (lanes
labeled “inputs”). Immunocomplexes were precipitated using TrueBlot antimouse IgG beads
(eBioscience), following the manufacturer’s instructions, and suspended in sample buffer
containing freshly added 50 mM DTT. After Western blot, the filter was developed with anti-
U1 snRNP-70K protein (U1-70K), using horseradish peroxidase-conjugated rabbit TrueBlot
secondary antibody (eBioscience). The filter was reprobed additionally with anti-SF2/ASF
monoclonal antibody (SF2), using horseradish peroxidase-conjugated rabbit TrueBlot
secondary antibody (eBioscience). As specificity control, the filter was reprobed with an
unrelated anti-HP1 antibody (HP1 ). IP, Immunoprecipitation; LY, LY294002.
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eIF4E-BP1, a competitive inhibitor of cap-dependent
translation, and therefore suppressing its activity (28).
We have shown that RA treatment induced an increase in
the phosphorylation of 4E-BP1 that could be abolished by
inhibition of PI3K but not by inhibition of the ERK
MAPK pathway. Therefore, despite the good correlation
between mTOR activity and the phosphorylation of 4E-
BP1, as reported elsewhere (28), additional mechanisms
depending on the activity of the ERK MAPK pathway
(37) appear to contribute to the establishment of a RA-
dependent mRNA translation control. Translational
control by RA is involved in important physiological
aspects of the neuronal activity, as is synaptic plastic-
ity. RA increases dendritic growth in hippocampal neu-
rons by mechanisms related to that described here, in
which a membrane-associated RAR regulates transla-
tion of specific mRNAs by activation of the ERK and
mTOR pathways (38, 39).
The results shown here contribute to
the idea that transcriptional and tran-
scription-independent actions elicited by
nuclear hormone receptors are integrated
and converge at multiple levels in the reg-
ulation of gene expression. At the level of
transcription, transcriptional actions elic-
ited by promoter-bound receptors are
potentiated by transcription-independent
actions acting at the level of chromatin
remodeling and cofactor recruitment, in
which phosphorylation of the receptor
appears to play an important role (11–
14). At the level of splicing, coactivator-
mediated cotranscriptional regulation,
which depends onDNA-bound receptors
(33–36), could converge with the signal-
ing-dependent regulation of splicing de-
scribed here, which relies on the phos-
phorylation of pre-mRNA-bound SFs.
Finally, convergence at the gene expres-
sion level could involve the specific regu-
lation of mRNA translation, depending
on signaling events initiated by the recep-
tor through its rapid transcription-inde-
pendent actions.
Materials and Methods
Cell culture and treatments
SH-SY5Y human neuroblastoma cells
(American Type Culture Collection no.
CRL-2266;Manassas, VA) were cultured in
DMEMwith 10% FBS, 100 U/ml penicillin,
and 100 g/ml streptomycin. Cell cultures
were kept in a humidified incubator at 37 C with 5% CO2. The
medium was replaced every 3 d, and the cells were split before
they reached confluence. LY294002, U0126, AMD, and all-
trans-retinoic acid were purchased from Sigma (St. Louis,
MO). The different compounds were dissolved in dimethyl-
sulfoxide and added to the culture medium at the indicated
concentrations.
Nuclei preparation
Phosphate buffer was avoided through the procedure, be-
cause phosphate ions interfere with subsequent phosphoprotein
affinity chromatography. Cells were washed and suspended
with ice-cold TBS (10 mM Tris-HCl, pH 7.4; 150 mM NaCl).
After centrifugation, cells were resuspended in 15 mM Tris-HCl
(pH 7.4), 60 mM KCl, 0.15 mM spermine, 0.5 mM spermidine, 2
mM EDTA, 1 mM dithiothreitol (DTT), 0.5 M Sucrose, 0.1 mM
phenylmethylsulfonyl fluoride, 1 mM NaF, 10 g/ml aprotinin,
1 g/ml leupeptin, 1 mM sodium orthovanadate). Cell suspen-
sion was mixed with one volume of the same buffer containing
0.2%Nonidet P-40 and incubated for 10–15min on ice. Nuclei
FIG. 8. RA treatment, through the activation of signaling pathways, influences the
regulation of mRNA translation. A, Schematic representation of the reporter genes used for
the analysis of mRNA translation regulation. [Adapted from Ref. 26.]. B, The effect of the RA
treatment on the translation of the LCS-EDA luciferase reporters. Neuroblastoma cells were
transfected in parallel reactions with either the LCS-EDA or the LCS-EDAmt luciferase
reporters, together with a promoterless Renilla luciferase reporter as internal control. After
transfection, neuroblastoma cells were treated with 1 M RA in the presence of LY294002
(10 M) or U0126 (10 M) as indicated. The ratio between the activities of the LCS-EDA and
the LCS-EDAmt reporters, normalized for the efficiency of the transfection, is represented for
control cells and cells treated with RA (1 M, 24 h) alone (solid bars) or in the presence of the
inhibitors LY294002 (10 M, light gray bars) and U0126 (10 M, dark gray bars) as indicated.
Asterisk on RA-treated sample indicates a statistically significant difference with respect to
control (P  0.004). All the other samples were not statistically different from control.
(ANOVA plus Bonferroni post hoc test). C, RA-induced changes in the phosphorylation of
eIF4E-BP1. Cells were treated with RA (1 M, 15 min) alone or in the presence of the
inhibitors LY294002 (10 M) and U0126 (10 M) as indicated, and cell extracts were
prepared. The phosphorylation state of 4E-BP1 was analyzed by Western blot with specific
antibodies against the phosphorylated form of the protein (P-4E-BP1). The filter was
reprobed finally with antibodies against total 4E-BP1 (4E-BP1). Each lane contains 30 g of
total protein. D, Effect of PI3K and MEK inhibitors in the activation of mTOR and p70S6
kinases by RA. Cells were treated with RA (1 M, 15 min) alone or in the presence of the
inhibitors LY294002 (10 M) and U0126 (10 M) as indicated, and whole-cell extracts were
prepared. The phosphorylation state of Akt, mTOR, and p70S6 kinases was analyzed by
Western blot with specific antibodies against the phosphorylated forms of the kinases (P-Akt,
P-mTOR, and P-p70S6). The filter was reprobed finally with antibodies against total Akt (Akt).
Each lane contains 30 g of total protein. LY, LY294002.
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were pelleted by centrifugation at 800 g for 10 min at 4 C and
washed with the same buffer without detergent. The nuclei were
repelleted, and the nuclear pellets were stored at 	80 C.
Protein extracts, SDS-PAGE, and Western blot
Whole-cell extracts were obtained by lysis of the cells in lysis
buffer (50 mM Tris-HCl, pH 7.4; 150 mMNaCl) containing 1%
Nonidet P-40, protease (1 mM phenylmethylsulfonyl fluoride,
10 g/ml aprotinin, and 10 g/ml leupeptin) and phosphatase
inhibitors (1 mM sodium orthovanadate, 1 mM NaF). After 30
min incubation on ice, the lysate was cleared by centrifugation
(16,100  g, 10 min, 4 C), and protein concentration was de-
termined using detergent-compatible Bio-Rad DC Protein assay
(Bio-Rad Laboratories, Inc., Hercules, CA).
Total nuclear extracts were obtained by lysis of the crude
nuclear fraction in lysis buffer as above. SDS-PAGE and West-
ern blot analysis of proteins were performed using standard
methods as described elsewhere (9). 2DE-Western blot was per-
formed similarly after 2DE (isoelectrofocusing/SDS-PAGE) (see
below). Antibodies against Akt 1/2, hnRNP-C1/C2 hnRNP-K,
Nucleophosmin SF2/ASF, U1 snRNP-70K, andHP1were pur-
chased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA).
Antibodies against phospho-mTOR (Ser2448), phospho-p70S6
kinase (Thr389), phospho-4E-BP1 (Thr37/46), phospho-S/T
Akt substrates, and 4E-BP1 were obtained from Cell Signaling
Technology (Beverly,MA). Antibodies against phosphotyrosine
(4G10) were from Upstate Biotechnology, Inc. (Lake Placid,
NY). Antibodies against histone H1.5 and HMGB1 were ob-
tained from Abcam PLC (Cambridge, UK), and those against
phosphoserine were obtained from QIAGEN. Horseradish per-
oxidase-conjugated secondary antibodies were obtained from
GE Healthcare (Piscataway, NJ) and Jackson ImmunoResearch
Laboratories, Inc. (West Grove, PA). Chemiluminescent signals
were developed with ECL or ECL Plus (GE Healthcare) and
images were capturedwith a LAS3000 Imager (Fuji Film Europe
GmBH, Du¨sseldorf, Germany). Staining of SDS-PAGE gels with
phosphoprotein-specific ProQ-Diamond dye, destaining, and
subsequent restaining with Sypro Ruby dye was performed as
recommended by the manufacturers (Molecular Probes, Inc.,
Eugene, OR; and Invitrogen, Carlsbad, CA). Detection of the
fluorescent bands was made using a FLA5000 scanner with
excitation lasers of 532 and 473 nm (Fuji Film).
Immunoprecipitation
Immunoprecipitation was carried out with the TrueBlot im-
munoprecipitation system (eBioscience, SanDiego, CA), follow-
ing the instructions of the manufacturer. For immunoprecipita-
tion, approximately 200 g protein from nuclear extracts
prepared as above was incubated with 25 l of mouse TrueBlot
IgG beads for 30 min at 4 C in 500 l of lysis buffer. After
centrifugation, the precleared lysate was incubated with 4 g
anti-SF2/ASF monoclonal antibody during 1 h at 4 C. As spec-
ificity control, parallel reactions with an unrelated antibody
were set. After addition of 50 l of mouse TrueBlot IgG beads,
the mixture was incubated under rotation during 16 h at 4 C.
The immunocomplexes were recovered by centrifugation,
washed three times with lysis buffer and resuspended in sample
buffer containing freshly added 50mMDTT.Western blot anal-
ysis of the immunocomplexes was carried out with primary
antibodies against U1-snRNP-70K, SF2/ASF and HP1, and
horseradish peroxidase-conjugated TrueBlot secondary anti-
bodies (eBioscience).
Phosphoprotein enrichment by
affinity chromatography
Phosphoprotein-enriched fraction from nuclear proteins was
obtained by affinity chromatography with the phosphoprotein
purification kit (QIAGEN), following the instructions of the
manufacturer. Benzonase was used at twice the recommended
concentration because of the high amount of nucleic acids
present in the cell nucleus. For each preparation 2.5 mg of nu-
clear proteins was used. After running the column, protein-
containing fractions were desalted and concentrated with
Nanosep 10K ultrafiltration spin columns (Pall Corp., Port
Washington, NY).
2DE
For 2DE, 125 g of nuclear phosphoprotein fractions was
precipitated with 100% acetone and resuspended in 2DE-sample
buffer (8Murea, 4%3-[(3-Cholamidopropyl) dimethylammonio]-
1-propanesulfonate, 32mMDTT,0.002%bromophenol blue, and
2% of the corresponding ampholytes). 2DE was performed with
isoelectrofocusing as first dimension and denaturing SDS-PAGE
(12.5%) as second following standard protocols. Immobilized pH
gradient strips (ImmobilineDryStryp, 7 cm;GEHealthcare) forpH
3–10 or 4–7were used following the recommendation of theman-
ufacturer. 2DE gels were stained with CBB (SimplyBlue, Invitro-
gen), and scanned. Matched gel pairs from samples from RA-
treated or untreated cells were compared with the PD-Quest
package (Bio-Rad). For 2DE-Western blots 25–30 g of total nu-
clear extract was electrophoresed as above and transferred to ni-
trocellulosemembranes. For validation experiments, 25g of total
nuclear protein extract lysed as above but omitting phosphatase
inhibitors, was incubatedwith 400U -protein phosphatase (New
England Biolabs, Beverly, MA) in 50 mM Tris-HCl (pH 7.5), 100
mMNaCl, 2mMMnCl2, 2mMDTT,0.1mMEGTA,0.01%Brij 35
during 60 min at 30 C. Finally proteins were precipitated with
acetone and electrophoresed as indicated above.
Protein identification by MS
Relevant spots were manually extracted from the gel and
reduced with DTT, alkylated with iodacetamide, and digested
with trypsin (Roche Applied Science, Mannheim, Germany).
The peptide mix was dried under vacuum and suspended in
50% acetonitrile, 0.1% trifluoroacetic acid (TFA). For peptide
fingerprinting by MALDI-TOF, the sample was analyzed in a
4700 Proteomic analyzer MALDI-TOF/TOF (Applied Biosys-
tems, Foster City, CA). Peptide fingerprint was identified using
theMASCOTsoftware (Matrix Science, Boston,MA). For peptide
sequencing by collision-induced dissociation-MS/MS, peptide
sample is ionized by nanoelectrospray, using a Q-Trap spectrom-
eter (Applied Biosystems). Selected double- or triple-charged ions
were fragmented, and the sequences of the peptides were obtained
by manual interpretation of the fragmentation spectra.
iTRAQ assay
Phosphoprotein eluates obtained from nuclear extracts of
untreated cells or cells treated with RA (1M) for 15 and 30min
were desalted by chloroform/methanol precipitation. Samples
(100 g of protein) were reduced with phosphine and cysteins
blocked with methyl methanethiosulfonate. After trypsin diges-
tion, the peptide mixtures were labeled with iTRAQ labeling
reagents, following the instructions of the supplier. Reporter of
mass 114, 116, and 117 were used for control, RA-15 min, and
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RA-30min samples, respectively. Equal amounts of each sample
were mixed and dried. Samples were resuspended in buffer A
(20mM triethanolamine in water) and loaded onto a Gemini 3
C18 110A 150-  4-mm column (Phenomenex, Torrance, CA)
equilibrated in the same buffer. Elution was performed with a
5–45% linear gradient of buffer B (20 mM triethanolamine in
acetonitrile) of 60 min at a flow rate of 150 l/min. Twelve
fractions were collected, acidified with 10% TFA, and dried by
centrifugation in vacuum. Each fraction was resuspended in 18
l of 5% acetonitrile, 0.1% TFA, and 5 l of the sample was
loaded onto a trap column (PepMap C18, 300 m 5 mm; LC
Packings, Amsterdam, The Netherlands) and desalted with
0.1% TFA at 40 l/min during 5 min. The peptides were then
loaded onto an analytical column (PepMap C18 3  100A, 75
m  15 cm, LC Packings) equilibrated in 0.1% formic acid.
Elution was carried out with a linear gradient 25–50% of sol-
vent B (95% acetonitrile, 0.1% formic Acid) in 120 min at a
flow rate of 300 nl/min. The eluted peptides were analyzed with
a nano-ESI-Q-TOF mass spectrometer (QSTAR-XL; Applied
Biosystems) in an information-dependent acquisition mode.
MS/MS data were analyzed using ProteinPilot version 2.0 (Ap-
plied Biosystems), which uses the Paragon algorithm to perform
database matching for protein identification and comparative quan-
tification, and Progroup algorithm for protein grouping to remove
redundant hits. The Swiss-Prot Homo sapiens protein database
was used for all searches. All reported data were based on more
than 95% confidence for protein identification as determined by
ProteinPilot. For relative quantification, only those changes having
a statistically significant change at P 0.05 were considered.
Transfections, RNA extraction, RT-PCR, and
luciferase assay
The E1A minigene splicing reporter plasmid (40) was trans-
fected to SH-SY5Y neuroblastoma cells using Escort V transfec-
tion reagent (Sigma), following the recommendations of the sup-
plier. Plasmid DNA (4 g) was used for 60 mm plate. FBS (1%)
was added to the cells 3–4 h after transfection. Cells were pre-
treated, 24 h after transfection, for 1 h with inhibitors or vehicle
as indicated after which RA was added for 24 h in the presence
of the inhibitors. Total RNA was isolated using QuickGene
RNA cultured cell HCkit S (Fuji Film), and contaminatingDNA
was digested with RQ DNase I (Promega Corp., Madison, WI).
cDNAwas prepared by reverse transcription using oligo-deoxy-
thymidine16 primer andMoloneymurine leukemia virus reverse
transcriptase (Promega) with 1 g of RNA template in 25 l
reaction volume. An aliquot (2.5 l) was then used for PCR (25
l) with Taq DNA polymerase (Biotools, Madrid, Spain). The
E1A splice formswere detected by PCR using E1A primers (E1A
forward: 5-GTTTTCTCCTCCGAGCCGCTCCGA; and E1A
reverse: 5-CTCAGGCTCAGGTTCAGACACAGG), with the
following PCR steps: one cycle of 95 C for 5min; 24 cycles of 95
C for 30 sec, 62 C for 20 sec, and 72 C for 40 sec; and one cycle
of 72 C for 10 min. PCR products were separated on a 2%
agarose gel, stained with ethidium bromide, documented, and
quantified. The mean and SD values for each isoform were cal-
culated from three independent experiments.
Reporter plasmids pLCS-EDAwt and pLCS-EDAmt (26) and
promoterless Renilla luciferase (pGL4.70, Promega) were trans-
fected to SH-SY5Y neuroblastoma using Lipofectamine 2000 re-
agent (Invitrogen), following the recommendations of the supplier.
The corresponding firefly luciferase reporter (4 g) was cotrans-
fected with 1 g of the Renilla reporter for each dish of a six-well
microplate. FBS (1%) was added to the cells 3–4 h after transfec-
tion. cells were pretreated, 24 h after transfection, for 1 h with
inhibitors or vehicle as indicated after which RA was added for
24 h in the presence of the inhibitors. Luciferase activities in cell
lysates were measured using the Dual-Luciferase Reporter Assay
System (Promega), following the instructions of the manufacturer.
Firefly luciferase activity values were normalized for Renilla lucif-
erase values, and the results are expressed asmean SD from three
independent experiments performed in duplicate.
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